PUBLISHER: Persistence Market Research | PRODUCT CODE: 1612838

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1612838

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

PUBLISHED: December 9, 2024

PAGES: 188 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Persistence Market Research has recently released a comprehensive report on the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Infectious Disease In-vitro Diagnostics Market Size (2024E): US$ 44.5 Bn
Projected Market Value (2031F): US$ 61.2 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

The Infectious Disease In-vitro Diagnostics market refers to diagnostic tests used for detecting infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic tests are essential in the early detection, management, and treatment of infectious diseases. The market is driven by rising global infectious disease prevalence, technological advancements in diagnostic technologies, and an increasing need for rapid and accurate diagnostic tools, especially in the wake of global pandemics. The market encompasses various segments, including molecular diagnostics, immunoassays, and microbiology testing.

Market Growth Drivers:

Several factors are contributing to the growth of the global Infectious Disease IVD market, including the rising incidence of infectious diseases, especially in developing regions, and growing healthcare infrastructure. Increasing awareness about early diagnosis and the growing demand for point-of-care testing (POCT) for infectious diseases are further propelling market growth. The need for accurate and rapid diagnostic tools is also rising due to the increasing frequency of outbreaks of diseases such as COVID-19, tuberculosis, HIV, and malaria. Additionally, technological advancements in molecular diagnostics and next-generation sequencing (NGS) are expected to drive the market forward.

Market Restraints:

Despite its growth potential, the Infectious Disease IVD market faces challenges such as high costs associated with advanced diagnostic tests, particularly in low-income regions. Regulatory hurdles in some countries, along with the need for extensive validation and certification of diagnostic products, may also limit market expansion. Moreover, the lack of awareness in remote areas regarding the availability and benefits of in-vitro diagnostics poses a barrier to the widespread adoption of diagnostic tools.

Market Opportunities:

The Infectious Disease IVD market presents significant opportunities, particularly in emerging economies, where the demand for better diagnostic tools is growing due to the rising burden of infectious diseases. Advancements in molecular diagnostics, including PCR-based technologies and CRISPR, offer new opportunities for innovation and expansion. Further, the increasing trend toward personalized medicine and the development of multiplex testing platforms provide growth avenues for market players. Additionally, the rise in collaborations between diagnostic companies and healthcare providers is expected to open new opportunities for market expansion.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the global Infectious Disease IVD market?
Which diagnostic technologies and testing platforms are leading the market in terms of demand and revenue?
How are advancements in molecular diagnostics and PCR technologies influencing the Infectious Disease IVD market?
Who are the leading players in the Infectious Disease IVD market, and what strategies are they employing to maintain their market positions?
What are the emerging trends and future prospects in the global Infectious Disease IVD market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Infectious Disease IVD market, such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, are focusing on enhancing their product portfolios, including rapid diagnostics and molecular testing platforms. These companies are investing in innovative technologies such as real-time PCR, next-generation sequencing (NGS), and point-of-care testing solutions. Collaborations with healthcare providers, research institutions, and public health organizations are critical to expanding market reach. Moreover, focusing on regulatory compliance, product differentiation, and technological advancements will help companies maintain a competitive edge and capitalize on the growing demand for efficient and accurate infectious disease diagnostics.

Key Companies Profiled:

QIAGEN
Becton, Dickinson and Company
bioMerieux SA
F. Hoffmann-La Roche, Ltd.
Hologic, Inc. (Gen Probe)
Abbott
Quidel Corporation
Siemens Healthineers AG
Bio-Rad Laboratories, Inc.
Danaher
OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

Instruments
Reagents
Software and Services

By Technology

Immunoassay
Molecular Diagnostics
Microbiology

By Application

MRSA
Clostridium Difficile
Respiratory Virus
TB and Drug-resistant TB
Gonorrhea
HPV
HIV
Hepatitis C
Hepatitis B
COVID-19

By End User

Point-of-care
Central Laboratories

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Product Code: PMRREP33205

1. Executive Summary

1.1. Global Infectious Disease In-Vitro Diagnostics Market Snapshot, 2024 - 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. Parent Market Analysis
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis

4. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
4.3. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  - 4.3.3.1. Instruments
  - 4.3.3.2. Reagents
  - 4.3.3.3. Software and Services
4.4. Market Attractiveness Analysis: Product Type
4.5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Technology
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
  - 4.5.3.1. Immunoassay
  - 4.5.3.2. Molecular Diagnostics
  - 4.5.3.3. Microbiology
  - 4.5.3.4. Others
4.6. Market Attractiveness Analysis: Technology
4.7. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Application
- 4.7.1. Introduction / Key Findings
- 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
- 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
  - 4.7.3.1. MRSA
  - 4.7.3.2. Clostridium Difficile
  - 4.7.3.3. Respiratory Virus
  - 4.7.3.4. TB and Drug-resistant TB
  - 4.7.3.5. Gonorrhea
  - 4.7.3.6. HPV
  - 4.7.3.7. HIV
  - 4.7.3.8. Hepatitis C
  - 4.7.3.9. Hepatitis B
  - 4.7.3.10. COVID-19
  - 4.7.3.11. Others
4.8. Market Attractiveness Analysis: Application
4.9. Global Infectious Disease In-Vitro Diagnostics Market Outlook: End User
- 4.9.1. Introduction / Key Findings
- 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
- 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
  - 4.9.3.1. Point-of-care
  - 4.9.3.2. Central Laboratories
  - 4.9.3.3. Others
4.10. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 6.2.1. By Country
- 6.2.2. By Product Type
- 6.2.3. By Technology
- 6.2.4. By Application
- 6.2.5. By End User
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 6.4.1. Instruments
- 6.4.2. Reagents
- 6.4.3. Software and Services
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 6.5.1. Immunoassay
- 6.5.2. Molecular Diagnostics
- 6.5.3. Microbiology
- 6.5.4. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 6.6.1. MRSA
- 6.6.2. Clostridium Difficile
- 6.6.3. Respiratory Virus
- 6.6.4. TB and Drug-resistant TB
- 6.6.5. Gonorrhea
- 6.6.6. HPV
- 6.6.7. HIV
- 6.6.8. Hepatitis C
- 6.6.9. Hepatitis B
- 6.6.10. COVID-19
- 6.6.11. Others
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 6.7.1. Point-of-care
- 6.7.2. Central Laboratories
- 6.7.3. Others
6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Technology
- 7.2.4. By Application
- 7.2.5. By End User
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 7.4.1. Instruments
- 7.4.2. Reagents
- 7.4.3. Software and Services
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 7.5.1. Immunoassay
- 7.5.2. Molecular Diagnostics
- 7.5.3. Microbiology
- 7.5.4. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 7.6.1. MRSA
- 7.6.2. Clostridium Difficile
- 7.6.3. Respiratory Virus
- 7.6.4. TB and Drug-resistant TB
- 7.6.5. Gonorrhea
- 7.6.6. HPV
- 7.6.7. HIV
- 7.6.8. Hepatitis C
- 7.6.9. Hepatitis B
- 7.6.10. COVID-19
- 7.6.11. Others
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 7.7.1. Point-of-care
- 7.7.2. Central Laboratories
- 7.7.3. Others
7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Technology
- 8.2.4. By Application
- 8.2.5. By End User
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 8.4.1. Instruments
- 8.4.2. Reagents
- 8.4.3. Software and Services
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 8.5.1. Immunoassay
- 8.5.2. Molecular Diagnostics
- 8.5.3. Microbiology
- 8.5.4. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 8.6.1. MRSA
- 8.6.2. Clostridium Difficile
- 8.6.3. Respiratory Virus
- 8.6.4. TB and Drug-resistant TB
- 8.6.5. Gonorrhea
- 8.6.6. HPV
- 8.6.7. HIV
- 8.6.8. Hepatitis C
- 8.6.9. Hepatitis B
- 8.6.10. COVID-19
- 8.6.11. Others
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 8.7.1. Point-of-care
- 8.7.2. Central Laboratories
- 8.7.3. Others
8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Technology
- 9.2.4. By Application
- 9.2.5. By End User
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 9.4.1. Instruments
- 9.4.2. Reagents
- 9.4.3. Software and Services
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 9.5.1. Immunoassay
- 9.5.2. Molecular Diagnostics
- 9.5.3. Microbiology
- 9.5.4. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 9.6.1. MRSA
- 9.6.2. Clostridium Difficile
- 9.6.3. Respiratory Virus
- 9.6.4. TB and Drug-resistant TB
- 9.6.5. Gonorrhea
- 9.6.6. HPV
- 9.6.7. HIV
- 9.6.8. Hepatitis C
- 9.6.9. Hepatitis B
- 9.6.10. COVID-19
- 9.6.11. Others
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 9.7.1. Point-of-care
- 9.7.2. Central Laboratories
- 9.7.3. Others
9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Technology
- 10.2.4. By Application
- 10.2.5. By End User
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 10.4.1. Instruments
- 10.4.2. Reagents
- 10.4.3. Software and Services
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 10.5.1. Immunoassay
- 10.5.2. Molecular Diagnostics
- 10.5.3. Microbiology
- 10.5.4. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 10.6.1. MRSA
- 10.6.2. Clostridium Difficile
- 10.6.3. Respiratory Virus
- 10.6.4. TB and Drug-resistant TB
- 10.6.5. Gonorrhea
- 10.6.6. HPV
- 10.6.7. HIV
- 10.6.8. Hepatitis C
- 10.6.9. Hepatitis B
- 10.6.10. COVID-19
- 10.6.11. Others
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 10.7.1. Point-of-care
- 10.7.2. Central Laboratories
- 10.7.3. Others
10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Technology
- 11.2.4. By Application
- 11.2.5. By End User
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 11.4.1. Instruments
- 11.4.2. Reagents
- 11.4.3. Software and Services
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
- 11.5.1. Immunoassay
- 11.5.2. Molecular Diagnostics
- 11.5.3. Microbiology
- 11.5.4. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
- 11.6.1. MRSA
- 11.6.2. Clostridium Difficile
- 11.6.3. Respiratory Virus
- 11.6.4. TB and Drug-resistant TB
- 11.6.5. Gonorrhea
- 11.6.6. HPV
- 11.6.7. HIV
- 11.6.8. Hepatitis C
- 11.6.9. Hepatitis B
- 11.6.10. COVID-19
- 11.6.11. Others
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 11.7.1. Point-of-care
- 11.7.2. Central Laboratories
- 11.7.3. Others
11.8. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2023
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. QIAGEN
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Products
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Becton, Dickinson and Company
- 12.3.3. bioMerieux SA
- 12.3.4. F. Hoffmann-La Roche, Ltd.
- 12.3.5. Hologic, Inc. (Gen Probe)
- 12.3.6. Abbott
- 12.3.7. Quidel Corporation
- 12.3.8. Siemens Healthineers AG
- 12.3.9. Bio-Rad Laboratories, Inc.
- 12.3.10. Danaher
- 12.3.11. OraSure Technologies, Inc.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ